RNAi therapeutics company Alnylam Pharmaceuticals Inc reported positive interim data from its ongoing Phase 1 study of ALN-AGT. The company is evaluating ALN-AGT …
Alnylam Pharmaceuticals (ALNY) has announced positive Phase 3 results from the ILLUMINATE-A study of lumasiran for the treatment of primary hyperoxaluria type 1 …
Markets are plunging, taking a serious hit as the coronavirus spreads rapidly throughout the world. So far, the worst of the outbreak is …
The calendar might have flipped to 2020, but that doesn’t mean everything has changed. Investors are still scouring the Street in search of …
Dicerna Pharmaceuticals (NASDAQ:DRNA) shares are shooting up over 30% faster than Jack’s magic bean sparking right into a giant beanstalk. Why the excitement?
Analyst praises Alnylam’s patisiran as best-in-class, even more confident in its safety and tolerability profile.
Tesla Motors Inc Tesla Motors Inc (NASDAQ:TSLA) shares dropped nearly 4% today after Goldman Sachs analyst David Tamberrino downgraded the electric car giant from Buy to …
Analysts offer insights into a volatile biotech-verse amid Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares dipping on news of a program termination and Aurinia Pharmaceuticals (NASDAQ:AUPH) soaring on …
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) investors are having a rough morning after the RNAi therapeutics company announced that it has decided to discontinue development of revusiran, an …
This morning Alnylam Pharma (NASDAQ:ALNY) announced that it initiated a Phase 1/2 clinical trial for ALN-CC5 for complement-mediated diseases. Initial data is expected in …
